Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STAR-TREC organ preservation study in early-stage rectal cancer
NL-OMON59858Phase 2Recruiting
- Sponsor
- Radboud University Medical Center
- Start
- Oct 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of capecitabine in rectal adenocarcinoma and rectal cancer, sponsored by Radboud University Medical Center. Primary endpoint: Successful organ preservation at 24 months. Started Oct 2024; status: recruiting.
02
Drugs
capecitabine
03
Conditions
rectal adenocarcinomarectal cancer
Beyond the preview
Go deeper on NL-OMON59858.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59858.